

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)  
Recombinant Antibody  
Catalog # APR10399**

**Specification**

---

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">Q9NP84</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Additional Information**

**Target/Specificity**

TNFRSF12A / TWEAKR / CD266

**Endotoxin**

< 0.001EU/ µg,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Protein Information**

**Name** TNFRSF12A

**Synonyms** FN14

**Function**

Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.

**Cellular Location**

Membrane; Single-pass type I membrane protein.


**Tissue Location**

Highly expressed in heart, placenta and kidney. Intermediate expression in lung, skeletal muscle and pancreas


**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Images**

Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) is more than 98.7%, determined by SEC-HPLC.